Aquarius were part of a recent feasibility trial looking at whether provision of a same day test and treatment service for chlamydia in further education colleges increased uptake of chlamydia testing and treatment. The results of the trial were published this week in Clinical Microbiology and Infection and are available online.
Work has begun to develop a digital value proposition tool for a novel rapid sexually transmitted infection (STI) test
London, UK, 14 August 2017
Aquarius Population Health, a leading independent health economics consultancy, has recently been awarded an 18-month Innovate UK grant in collaboration with Atlas Genetics Ltd and the Applied Diagnostic Research and Evaluation Unit at St George’s University of London (total £2,000,000). The funding will be used to develop evidence for health services to support the introduction of a new rapid diagnostic test. In 30-minutes the test can diagnose multiple sexually transmitted infections including chlamydia and gonorrhoea – infections which could take up to a week to diagnose using the current laboratory testing systems.
We were a collaborator on a recent Innovate UK-funded SBRI project with Atlas Genetics and the Applied Diagnostic Research and Evaluation Unit at St George’s University of London. In this project, our team compared the overall costs, patient benefits and cost-effectiveness of three different multi-pathogen point-of-care testing strategies with the current strategy of microscopy and lab-based testing.
Personalised medicine is an emerging field that brings exciting changes to patient care. So, what exactly is personalised medicine and what are its benefits?
In the past, various terms have been used interchangeably: ‘stratified medicine’, ‘personalised medicine’ and ‘precision medicine’. These terms refer to data driven medicine, in which data can be a patient’s genetic makeup, molecular data or disposition to respond to therapy. These data allow for a targeted approach to prevention, diagnosis and treatment using technologies such as genomic medicine, diagnostic tests, predictive data analytics or real-time patient monitoring.
Our Managing Director, Elisabeth Adams, spoke in November about the importance of exploring the health economics of point of care testing (POCT) at the Royal Society of Medicine Telemedicine and eHealth event in London.
Why is it important to explore the health economics of point of care testing (POCT)?
Evaluating the health economics of POCTs can help us better understand the cost, benefits and value of implementing these tests, compared to standard laboratory tests. We need to explore the acquisition costs of innovative technology like POCTs compared to standard tests, as well as the benefits generated for patients, service providers, clinicians and public health in general. Benefits can include faster results, better care, fewer complications, more efficient services and better use of resources, and knock-on benefits like reduced prevalence of disease. Those making purchasing decisions for new tests need evidence to prove the value of the tests.
January has been a busy month for Aquarius Population Health, and our team members have spoken at and attended several fascinating events. Our Managing Director, Dr Elisabeth Adams, presented at the invitation-only DHACA Day XI on the 18th January. Drawing from her extensive experience delivering health economic projects, Elisabeth provided key insights on how patient pathway mapping and economic evaluation help demonstrate the value of digital health products. Digital Health and Care Alliance (DHACA) is a non-for-profit organisation dedicated to sharing knowledge and advancing digital healthcare systems in the UK and Europe.
Dr Elisabeth Adams, Managing Director of Aquarius Population Health, presented on opportunities for rapid tests in influenza and HPV at international conferences in June.
This has been a busy week for the Aquarius Population Health team. We had two posters at the Society for Medical Decision Making in London (12-15th June), which Elisabeth presented. The posters showcased results from two studies we have done looking at the impact of implementing a rapid near-patient test for influenza and RSV. This was a collaborative project with Enigma Diagnostics and Guy’s and St Thomas’ NHS Trust. Results indicated that a rapid test could improve clinical management of patients with influenza, and could save commissioners money. It also illustrated how a rapid test could prevent unnecessary isolation bed days compared to current practice (presumptive isolation while waiting for results of the standard laboratory test results for influenza).